Savara Inc.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
United States
126 employees
Post-IPO Equity
Total: $414.10M
Biopharma, Biotechnology +1
General Information
United States
BounceWatch is an independent company data service, not affiliated with Savara Inc.. To contact Savara Inc., visit savarapharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Savara Inc. compare?
A PDF of Savara Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Savara Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biopharma
About Savara Inc.
Business keywords: biopharmaceuticals, rare respiratory diseases, clinical stage development, autoimmune pulmonary alveolar proteinosis, nontuberculous mycobacteria lung infection, cystic fibrosis, methicillin resistant staphylococcus aureus lung infection, drug development partnerships, orphan drug development, pulmonary medicine, indication expansion, product acquisitions, antibacterial activity, drug delivery, rare disease therapeutics
Services & Products
Target Customers
Funding Rounds & Investors (15)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $100.00M | 7 |
|
28 Jun 2024 |
| Post IPO Debt | $26.50M | 1 |
Silicon Valley Bank
|
22 Apr 2022 |
| Post IPO Debt | $26.50M | - |
|
01 Jan 2022 |
| Post IPO Equity | $130.00M | - |
|
11 Mar 2021 |
| Post IPO Equity | $26.80M | 1 |
Bain Capital Life Sciences
|
15 Jan 2020 |
| Grant | $5.00M | 1 |
|
29 Nov 2017 |
| Post IPO Equity | $47.00M | - |
|
26 Oct 2017 |
| Debt Financing | $15.00M | 1 |
Silicon Valley Bank
|
01 Apr 2017 |
| Series C | $20.00M | 5 |
|
01 Mar 2016 |
| Series C | Undisclosed | 1 |
|
30 Jul 2014 |
Latest News
View All
Savara Inc. Alternatives & Competitors
View All Alternatives
Clinical-stage biotech company focused on rare diseases and diseases with high unmet need
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class...
FAQ About Savara Inc.
Source: BounceWatch company record for Savara Inc., https://bouncewatch.com/company/savara-inc, updated 4 July 2026. When citing, please name BounceWatch and link this page.
